The Uveitis drugs in development market research report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Uveitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Uveitis and features dormant and discontinued products.
GlobalData tracks 71 drugs in development for Uveitis by 63 companies/universities/institutes. The top development phase for Uveitis is preclinical with 41 drugs in that stage. The Uveitis pipeline has 67 drugs in development by companies and four by universities/ institutes. Some of the companies in the Uveitis pipeline products market are: Palatin Technologies, BioMarck Pharmaceuticals and Elasmogen.
The key targets in the Uveitis pipeline products market include Tumor Necrosis Factor, Nuclear Factor Kappa B, and Myristoylated Alanine Rich C Kinase Substrate.
The key mechanisms of action in the Uveitis pipeline product include Tumor Necrosis Factor Inhibitor with six drugs in Phase II. The Uveitis pipeline products include 12 routes of administration with the top ROA being Ophthalmic and 13 key molecule types in the Uveitis pipeline products market including Small Molecule, and Synthetic Peptide.
Uveitis overview
Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors include infection, autoimmune or inflammatory disorder, and history of eye injury. Treatment includes steroid eye drops, anti-inflammatories, antibiotics, or antiviral medication.
For a complete picture of Uveitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
